Determinants of Human Immunodeficiency Virus Type 1 Baseline Susceptibility to the Fusion Inhibitors Enfuvirtide and T-649 Reside outside the Peptide Interaction Site

The peptide fusion inhibitor (PFI) enfuvirtide is the first of a new class of entry inhibitors to receive FDA approval. We previously determined the susceptibility of 55 PFI-naïve-patient isolates to enfuvirtide and a second peptide inhibitor, T-649. Seven of the 55 viral isolates were insusceptible...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Heil, Marintha L., Decker, Julie M., Sfakianos, Jeffrey N., Shaw, George M., Hunter, Eric, Derdeyn, Cynthia A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2004
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC434069/
https://ncbi.nlm.nih.gov/pubmed/15220433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.78.14.7582-7589.2004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky